1-(β-D-ribofuranosyl)-2-mercapto-5,6-dichlorobenzimidazole | 142356-77-2

• 分子结构分类: 有机化合物 - 核苷、核苷酸和类似物 - 苯并咪唑核糖核苷和核糖核苷酸
• 英文名称: 1-(β-D-ribofuranosyl)-2-mercapto-5,6-dichlorobenzimidazole
• 英文别名: 5,6-dichloro-2-mercapto-1-(β-D-ribofuranosyl)-benzimidazole；5,6-dichloro-1-β-D-ribofuranosylbenzimidazole-2-thione；5,6-Dichloro-1-(β-D-ribofuranosyl)benzimidazol-2-thione；(2R,3R,4S,5R)-2-(5,6-dichloro-2-sulfanylbenzimidazol-1-yl)-5-(hydroxymethyl)oxolane-3,4-diol
• CAS: 142356-77-2
• 化学式: C₁₂H₁₂Cl₂N₂O₄S
• 分子量: 351.21
• InChiKey: ZWYUQPPTOOZWEF-GWOFURMSSA-N

物化性质

• 沸点：
  598.9±60.0 °C(Predicted)
• 密度：
  1.81±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1.1
• 重原子数：
  21
• 可旋转键数：
  2
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.42
• 拓扑面积：
  117
• 氢给体数：
  4
• 氢受体数：
  5

反应信息

• 作为反应物：
  描述：

  1-(β-D-ribofuranosyl)-2-mercapto-5,6-dichlorobenzimidazole 在 4-二甲氨基吡啶 、 偶氮二异丁腈 、 四丁基氟化铵 、 三正丁基氢锡 、 N,N'-硫羰基二咪唑 作用下， 以 四氢呋喃 、 吡啶 、 1,2-二氯乙烷 、 N,N-二甲基甲酰胺 、 甲苯 、 乙腈 为溶剂， 反应 65.0h， 生成 5,6-dichloro-1-(2',3'-dideoxy-β-D-glycero-pent-2'-enofuranosyl)-2-mercaptobenzimidazole
  参考文献：
  名称：

  Mathe, Christophe; Perigaud, Christian; Gosselin, Gilles, Journal of the Chemical Society. Perkin transactions I, 1994, # 8, p. 1019 - 1024

  摘要：

  DOI：
• 作为产物：
  描述：

  邻二氯苯 在 镍 氢氧化钾 、 三氟甲磺酸三甲基硅酯 、 硫酸 、 三氧化硫 、 氢气 、 硝酸 、 sodium methylate 、 牛血清白蛋白 作用下， 以 乙醇 为溶剂， 反应 65.5h， 生成 1-(β-D-ribofuranosyl)-2-mercapto-5,6-dichlorobenzimidazole
  参考文献：
  名称：

  Synthesis and Antiviral Evaluation of 2-Mercapto-5,6-dichlorobenzimidazole-β-D-ribofuranonucleoside Derivatives

  摘要：

  2-Mercapto-5,6-dichlorobenzimidazole beta-D-ribofuranonucleoside derivatives 8-10 have been synthesized and their antiviral properties examined. According to the glycosylation procedure used, the beta-D-N-1 isomer (and the N,N-bis-riboside) or the beta D-S-2-isomer have been obtained. All the prepared compounds were tested for their activity against a variety of RNA and DNA viruses, but they did not show significant antiviral activity.

  DOI：

  10.1080/15257779408013253

文献信息

• Visible-light-induced aerobic oxidative desulfurization of 2-mercaptobenzimidazoles <i>via</i> a sulfinyl radical
  作者：Mei Fu、Xiaochen Ji、Yongtong Li、Guo-Jun Deng、Huawen Huang

  DOI：10.1039/d0gc02269a

  日期：——

  A mild transition-metal-free non-toxic aerobic photoredox system was found to enable highly efficient desulfurization of 2-mercaptobenzimidazoles. This viable catalytic system includes Rose Bengal in a low catalyst loading as a photosensitizer and cheap, non-toxic NaCl in a catalytic amount as an additive, combined with an oxygen atmosphere. This protocol provides an important alternative access to

  发现温和的不含过渡金属的无毒需氧光氧化还原系统可实现2-巯基苯并咪唑的高效脱硫。这种可行的催化系统包括低催化剂含量的Rose Bengal作为光敏剂，以及廉价的无毒NaCl（催化量）作为添加剂，并与氧气气氛相结合。该方案提供了重要的替代途径，可以以通常的高收率获得各种苯并咪唑和氘代苯并咪唑产品，并且对各种合成和药学上有用的功能具有良好的耐受性。机理研究表明，单电子转移和能量转移都可能在初始步骤发生，并且亚硫酰基自由基中间体参与了关键的脱硫过程。
• Polysubstituted benzimidazoles as antiviral agents
  申请人：The Regents of the University of Michigan

  公开号：US05646125A1

  公开（公告）日：1997-07-08

  This invention relates to novel polysubstituted benzimidazoles and compositions and their use in the treatment of viral infections. The polysubstituted benzimidazoles and compositions of the present invention exhibit antiviral properties against viruses of the herpes family, particularly human cytomegalovirus (HCMV) and herpes simplex viruses (HSV).

  本发明涉及新型多取代苯并咪唑及其组合物，以及它们在治疗病毒感染方面的应用。本发明的多取代苯并咪唑和组合物对疱疹病毒家族的病毒，尤其是人类巨细胞病毒（HCMV）和单纯疱疹病毒（HSV）表现出抗病毒特性。
• Treatment of herpes infections with polysubstituted benzimidazoles
  申请人：The Regents of the University of Michigan

  公开号：US05712255A1

  公开（公告）日：1998-01-27

  A method for treating a herpes viral infection comprising administering to the infected host a therapeutically effective amount of a compound, or a pharmaceutically acceptable salt or formulation thereof, selected from the group consisting of compounds having the following formula: ##STR1## wherein: R.sub.1 is H, R.sub.2 is Cl, R.sub.3 is Cl, R.sub.4 is H, R.sub.5 is Br and R.sub.6 is .beta.-D-ribofuranosyl (denoted compound 52 in the text); R.sub.1 is H, R.sub.2 is NO.sub.2, R.sub.3 is NO.sub.2, R.sub.4 is H, R.sub.5 is Cl and R.sub.6 is .beta.-D-ribofuranosyl (denoted compound 61 in the text); R.sub.1 is Cl, R.sub.2 is H, R.sub.3 is Cl, R.sub.4 is H, R.sub.5 is Cl and R.sub.6 is .beta.-D-ribofuranosyl (denoted compound 81 in the text); R.sub.1 is H, R.sub.2 is Cl, R.sub.3 is Cl, R.sub.4 is H, R.sub.5 is I and R.sub.6 is .beta.-D-ribofuranosyl (denoted compound 83a in the text); R.sub.1 is Br, R.sub.2 is Br, R.sub.3 is H, R.sub.4 is H, R.sub.5 is Cl and R.sub.6 is .beta.-D-ribofuranosyl (denoted compound 85 in the text); R.sub.1 is H, R.sub.2 is Br, R.sub.3 is Cl, R.sub.4 is H, R.sub.5 is Cl and R.sub.6 is .beta.-D-ribofuranosyl (denoted compound 95 in the text); R.sub.1 is H, R.sub.2 is Cl, R.sub.3 is Br, R.sub.4 is H, R.sub.5 is Cl and R.sub.6 is .beta.-D-ribofuranosyl (denoted compound 99 in the text); R.sub.1 is H, R.sub.2 is I, R.sub.3 is I, R.sub.4 is H, R.sub.5 is Cl and R.sub.6 is .beta.-D-ribofuranosyl (denoted compound 107 in the text); R.sub.1 is H, R.sub.2 is Cl, R.sub.3 is Cl, R.sub.4 is H, R.sub.5 is Cl and R.sub.6 is 2'-deoxy-.beta.-D-erythro-pentofuranosyl (denoted compound 111 in the text); R.sub.1 is H, R.sub.2 is Cl, R.sub.3 is Cl, R.sub.4 is H, R.sub.5 is Br and R.sub.6 is 2'-deoxy-.beta.-D-erythro-pentofuranosyl (denoted compound 112 in the text); R.sub.1 is Cl, R.sub.2 is Cl, R.sub.3 is Cl, R.sub.4 is Cl, R.sub.5 is Cl and R.sub.6 is (1,3-dihydroxy-2-propoxy)methyl (denoted compound 155 in the text); R.sub.1 is Cl, R.sub.2 is Cl, R.sub.3 is Cl, R.sub.4 is Cl, R.sub.5 is NH.sub.2 and R.sub.6 is (1,3-dihydroxy-2-propoxy)methyl (denoted compound 156 in the text); R.sub.1 is Cl, R.sub.2 is Cl, R.sub.3 is Cl, R.sub.4 is Cl, R.sub.5 is OCH.sub.3 and R.sub.6 is 2-hydroxyethoxymethyl (denoted compound 166a in the text); R.sub.1 is Cl, R.sub.2 is Cl, R.sub.3 is Cl, R.sub.4 is Cl, R.sub.5 is NH.sub.2 and R.sub.6 is 2-hydroxyethoxymethyl (denoted compound 167 in the text); and R.sub.1 is H, R.sub.2 is Cl, R.sub.3 is Cl, R.sub.4 is H, R.sub.5 is NH.sub.2 and R.sub.6 is benzyl (denoted compound 182 in the text).

  一种治疗单纯疱疹病毒感染的方法，包括向受感染宿主投与以下化合物中的一种，或其在药学上可接受的盐或制剂，所述化合物具有以下公式： ##STR1## 其中：R.sub.1为H，R.sub.2为Cl，R.sub.3为Cl，R.sub.4为H，R.sub.5为Br，R.sub.6为β-D-核糖呋喃（在文本中标记为化合物52）；R.sub.1为H，R.sub.2为NO.sub.2，R.sub.3为NO.sub.2，R.sub.4为H，R.sub.5为Cl，R.sub.6为β-D-核糖呋喃（在文本中标记为化合物61）；R.sub.1为Cl，R.sub.2为H，R.sub.3为Cl，R.sub.4为H，R.sub.5为Cl，R.sub.6为β-D-核糖呋喃（在文本中标记为化合物81）；R.sub.1为H，R.sub.2为Cl，R.sub.3为Cl，R.sub.4为H，R.sub.5为I，R.sub.6为β-D-核糖呋喃（在文本中标记为化合物83a）；R.sub.1为Br，R.sub.2为Br，R.sub.3为H，R.sub.4为H，R.sub.5为Cl，R.sub.6为β-D-核糖呋喃（在文本中标记为化合物85）；R.sub.1为H，R.sub.2为Br，R.sub.3为Cl，R.sub.4为H，R.sub.5为Cl，R.sub.6为β-D-核糖呋喃（在文本中标记为化合物95）；R.sub.1为H，R.sub.2为Cl，R.sub.3为Br，R.sub.4为H，R.sub.5为Cl，R.sub.6为β-D-核糖呋喃（在文本中标记为化合物99）；R.sub.1为H，R.sub.2为I，R.sub.3为I，R.sub.4为H，R.sub.5为Cl，R.sub.6为β-D-核糖呋喃（在文本中标记为化合物107）；R.sub.1为H，R.sub.2为Cl，R.sub.3为Cl，R.sub.4为H，R.sub.5为Cl，R.sub.6为2'-脱氧-β-D-erythro-戊呋喃核苷（在文本中标记为化合物111）；R.sub.1为H，R.sub.2为Cl，R.sub.3为Cl，R.sub.4为H，R.sub.5为Br，R.sub.6为2'-脱氧-β-D-erythro-戊呋喃核苷（在文本中标记为化合物112）；R.sub.1为Cl，R.sub.2为Cl，R.sub.3为Cl，R.sub.4为Cl，R.sub.5为Cl，R.sub.6为（1,3-二羟基-2-丙氧基）甲基（在文本中标记为化合物155）；R.sub.1为Cl，R.sub.2为Cl，R.sub.3为Cl，R.sub.4为Cl，R.sub.5为NH.sub.2，R.sub.6为（1,3-二羟基-2-丙氧基）甲基（在文本中标记为化合物156）；R.sub.1为Cl，R.sub.2为Cl，R.sub.3为Cl，R.sub.4为Cl，R.sub.5为OCH.sub.3，R.sub.6为2-羟基乙氧基甲基（在文本中标记为化合物166a）；R.sub.1为Cl，R.sub.2为Cl，R.sub.3为Cl，R.sub.4为Cl，R.sub.5为NH.sub.2，R.sub.6为2-羟基乙氧基甲基（在文本中标记为化合物167）；R.sub.1为H，R.sub.2为Cl，R.sub.3为Cl，R.sub.4为H，R.sub.5为NH.sub.2，R.sub.6为苄基（在文本中标记为化合物182）。
• Benzimidazole Ribonucleosides: Design, Synthesis, and Antiviral Activity of Certain 2-(Alkylthio)- and 2-(Benzylthio)-5,6-dichloro-1-(.beta.-D-ribofuranosyl)benzimidazoles
  作者：Rodrigo V. Devivar、Etsuko Kawashima、Ganapathi R. Revankar、Julie M. Breitenbach、Edward D. Kreske、John C. Drach、Leroy B. Townsend

  DOI：10.1021/jm00044a015

  日期：1994.9

  Several 2-alkylthio- and 2-benzylthio derivatives of 5,6-dichloro-1-(beta-D-ribofuranosyl)benzimidazole (DRB) have been designed and synthesized from 5,6-dichloro-1-(beta-D-ribofuranosyl)-benzimidazole-2-thione. All compounds were evaluated for activity against human cytomegalovirus (HCMV) and/or herpes simplex virus type-1 (HSV-1). Three different cytotoxicity assays were used to determine if the compounds were toxic to uninfected cells. Most of the 2-alkylthio compounds were either inactive against HCMV and HSV-1 or were active only at concentrations at or near those which produced toxicity in uninfected cells. The best separation between activity against HCMV and cytotoxicity was observed with the 2-benzylthio analog 7. This prompted us to synthesize the substituted 2-benzylthio analogs 11-23 using a Topliss Tree approach. None of these compounds were more active than compound 7; most of the analogs were weakly active against both HCMV and HSV-1, but the activity was not separated from cytotoxicity. On the basis of both antiviral and cytotoxicity data, compound 7 was the best compound in the series. It was more active against HCMV than DRB (the 2-unsubstituted analog), acyclovir, and foscarnet, but it was less active than ganciclovir.
• POLYSUBSTITUTED BENZIMIDAZOLES AS ANTIVIRAL AGENTS
  申请人：THE REGENTS OF THE UNIVERSITY OF MICHIGAN

  公开号：EP0556334A1

  公开（公告）日：1993-08-25